Lundbeck's bexicaserin granted Breakthrough Therapy Designation in China to treat seizures in severe rare epilepsies

Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA

Autonomix Medical secures new US patent to expand precision nerve-targeted therapies

Tempus selected by ARPA-H to provide CRO and testing services for ADAPT cancer programme

Novo Nordisk to acquire Akero Therapeutics in USD5.2bn deal to strengthen MASH pipeline

Zelluna receives positive MHRA feedback and advances UK clinical plans for ZI-MA4-1

C-Ray Therapeutics (Shanghai) presents 225Ac-PSMA-CY313 breakthrough clinical data at EANM 2025

TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences

Sanofi's AlphaMedix meets all primary endpoints in phase 2 study in gastroenteropancreatic neuroendocrine tumours

Aptamer Group wins GBP360,000 contract with global pharmaceutical company for radiopharmaceutical development

Oxford BioDynamics and UEA develop 96% accurate blood test for Chronic Fatigue Syndrome

Oncoinvent reports positive final Phase 1 results for Radspherin in ovarian cancer trial

Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation

Oncoinvent reports positive Phase 1 Radspherin trial data

Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio